Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy.
about
Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapyPharmacological interventions for the prevention and treatment of radiation colitis, enteritis and proctitisProtection against Radiotherapy-Induced ToxicityWhat Are the Best Questionnaires To Capture Anorectal Function After Surgery in Rectal Cancer?Radiation-induced small bowel disease: latest developments and clinical guidanceChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA.Therapeutic role of glutamine in management of radiation enteritis: a meta-analysis of 13 randomized controlled trialsUse of probiotics for prevention of radiation-induced diarrhea.Complementary strategies for the management of radiation therapy side effectsGlutamine: A novel approach to chemotherapy-induced toxicity.Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.Gastrointestinal complications of pelvic radiotherapy: are they of any importance?Improving the morbidity of anorectal injury from pelvic radiotherapy.A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy.N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAAssessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1The efficacy of oral glutamine in prevention of acute radiotherapy-induced esophagitis in patients with lung cancer.Role of triamcinolone in radiation enteritis management.Glutamine as a supplemental treatment in pediatric and adult oncology patients.ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context.Enterocutaneous fistula associated with malignancy and prior radiation therapy.The protective effects of glutamine on radiation-induced diarrhea.Radiation enteritis leading to intestinal failure: 1994 patient-years of experience in a national referral centre.Quality of life in colorectal cancer patients with diarrhoea after surgery: a longitudinal study.Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial.Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy.Prevention of acute radiation enteritis: efficacy and tolerance of glutamine.
P2860
Q24202360-BF355D89-B0A7-43F2-BF6D-50B5BAAA456DQ24234373-DC6533CA-8B64-4D7C-86B2-3643299367FCQ26741273-46E5CF45-A3DE-4410-A549-193DAAA7C3E1Q28085690-83C7AAE0-CA25-4F3D-A790-74CAAA732488Q28304957-95493EFD-DFEE-416F-B73B-F0D2B9AD2D67Q30318822-C50AB2F7-F4CC-4E90-AFCA-17BE8044C43DQ33601615-11C047F6-D042-46F8-B891-3C8312B1FED1Q33728405-D2A3B379-4B41-4323-8F73-52BE359D2AC2Q33787744-3DF9F18E-DBF7-4822-8933-A13E9A5CAC5FQ33886006-C17F6113-5E0D-480A-AF7A-9F2357C7A33BQ34323985-6775B403-DA25-467B-9A88-E5C5DC1BF471Q34462689-2ABB63BC-3DF3-44A3-A01C-BCEC5FA2399BQ35598210-BCD6C8E6-4922-497B-81D0-93801E54931EQ36414853-9A7FC2C9-B33B-48EE-8CD4-083B02AB6FA4Q36616769-15293A38-0F6B-455D-BB08-19A932E824A3Q37114350-344DF5DD-9C02-4633-B4AC-807A97FA0685Q37119415-7DA1A52E-207A-4329-88E3-A68B1A19A808Q37161133-C9A139A5-2C32-4916-8619-9868D4BE783EQ37601879-85B4413D-8423-45F0-80D3-5970133DE017Q37708033-D461D425-5D26-4190-BA7D-31861AFDFDCEQ38037134-3ACF5FD4-6DB7-46D4-9B34-058EB1FD8393Q38038330-81832AA7-1222-43BC-8515-B95FCAA1BC1AQ42110220-AD2F53C8-EA3D-4F57-8896-AC76A8311603Q43660651-F69172DC-7263-4064-8DEA-7393CDF24A70Q45364955-FC400231-DCFD-4B92-BCBB-66667CF61465Q45796115-69C1BFF6-4BEF-46B9-86B8-72827C8AFB83Q46738218-71E00BEE-AD6E-4435-8848-CBE808B46DD4Q47947065-CAE4F1B4-18DC-4281-BE6B-A45106790390Q48576232-CE1443C5-34E2-4D33-AA3A-66D799BCDF9C
P2860
Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Phase III double-blind study o ...... ving pelvic radiation therapy.
@en
Phase III double-blind study o ...... ving pelvic radiation therapy.
@nl
type
label
Phase III double-blind study o ...... ving pelvic radiation therapy.
@en
Phase III double-blind study o ...... ving pelvic radiation therapy.
@nl
prefLabel
Phase III double-blind study o ...... ving pelvic radiation therapy.
@en
Phase III double-blind study o ...... ving pelvic radiation therapy.
@nl
P2093
P921
P356
P1476
Phase III double-blind study o ...... ving pelvic radiation therapy.
@en
P2093
Albert R Frank
George P Engeler
Gregory E Meyers
James A Martenson
Jeff A Sloan
Miljenko V Pilepich
North Central Cancer Treatment Group
Paul J Novotny
Randy L Moore
Rodolfo E Urias
P304
P356
10.1200/JCO.2003.05.060
P407
P577
2003-05-01T00:00:00Z